Hewas also the senior biotechnology sell-side analyst on the equities team atFoster

Hewas also the senior biotechnology sell-side analyst on the equities team atFoster Stockbroking, and had corporate finance experience advising life sciencecompanies at Deloitte. About AvexaAvexa Limited is a Melbourne-based biotechnology company with a focus onresearch and development of small molecules for the treatment of infectiousdiseases. Prior to Scientia, MrGozlan was responsible for the largest biotechnology investment portfolio inAustralia as the institutional biotechnology analyst at Queensland InvestmentCorporation (QIC), a fund manager with over $50 billion AUD under management. I am excited to workwith the company`s management and board of directors as we look to move theproducts forward through development," stated Lawrence Gozlan.

Lawrence Gozlan is the CEO and founder of Scientia Capital, a specialised globalinvestment fund focused exclusively on life science. "I would also like to acknowledge John`s significant contribution to theAvexa board over the last two years and wish him well for his future." "Avexa is at a critical juncture with apricitabine currently in Phase III trialsand the remainder of the pipeline progressing on track. "We are thrilled to welcome Lawrence to our Board of Directors. His backgroundin the life science industry as both a leading analyst and investor brings aunique and important perspective to our organisation, and we look forward to hisguidance and leadership as we continue to grow," said Nathan Drona, chairman ofAvexa. See for a list of additional trademarks.

Other productor brand names may be trademarks or registered trademarks of their respectiveholders.The MathWorks, Inc.Dave Smith, Copyright Business Wire 2009. MELBOURNE, Australia--(Business Wire)--Avexa Limited (ASX:AVX) today announced the appointment of Lawrence Gozlan toits Board of Directors, replacing Dr John Sime who is retiring from the board.Dr Sime was appointed to the board as a non-executive director in June 2007, andMr Gozlan will replace him in this capacity effective immediately. Founded in 1984, The MathWorks employs more than 2,100 people in 15 countries,with headquarters in Natick, Massachusetts, USA. For additional information,visit MATLAB and Simulink are registered trademarks of The MathWorks, Inc.

MathWorks products are alsofundamental teaching and research tools in the world`s universities and learninginstitutions. Engineers and scientists worldwiderely on these product families to accelerate the pace of discovery, innovation,and development in automotive, aerospace, electronics, financial services,biotech-pharmaceutical, and other industries. The MathWorks Japan`s principal office is located at Akasaka Garden City 7F,4-15-1 Akasaka, Minato-ku, Tokyo, 107-0052. For more information on TheMathWorks Japan, please visit our web site at http:// About The MathWorksThe MathWorks is the leading developer of mathematical computing software.MATLAB, the language of technical computing, is a programming environment foralgorithm development, data analysis, visualization, and numeric computation.Simulink is a graphical environment for simulation and Model-Based Design ofmulti-domain dynamic and embedded systems.